Predictors of COVID-19 outcome in Parkinson's disease

Parkinsonism Relat Disord. 2020 Sep:78:134-137. doi: 10.1016/j.parkreldis.2020.08.012. Epub 2020 Aug 13.

Abstract

Introduction: Specific pre-existing medical conditions (e.g. hypertension or obesity), advanced age and male sex appear linked to more severe manifestations of SARS Co-V2 infection, thus raising the question of whether Parkinson's disease (PD) poses an increased risk of morbidity and mortality in COVID-19 patients.

Methods: In order to describe the outcome of COVID-19 in multi-centre a cohort of PD patients and explore its potential predictors, we gathered the clinical information of 117 community-dwelling patients with COVID-19 followed in 21 tertiary centres in Italy, Iran, Spain, and the UK.

Results: Overall mortality was 19.7%, with a significant effect of co-occurrence of dementia, hypertension, and PD duration.

Conclusions: The frailty caused by advanced PD poses an increased risk of mortality during COVID-19.

Keywords: COVID-19; Dementia; Outcome; Parkinson's disease.

MeSH terms

  • Aged
  • Aged, 80 and over
  • Antiparkinson Agents / therapeutic use
  • COVID-19 / epidemiology
  • COVID-19 / mortality*
  • Comorbidity
  • Deep Brain Stimulation
  • Dementia / epidemiology*
  • Female
  • Hospitalization / statistics & numerical data*
  • Humans
  • Hypertension / epidemiology*
  • Iran / epidemiology
  • Italy / epidemiology
  • Male
  • Middle Aged
  • Parkinson Disease / epidemiology*
  • Parkinson Disease / therapy
  • Risk Factors
  • Severity of Illness Index
  • Spain / epidemiology
  • Time Factors
  • United Kingdom / epidemiology

Substances

  • Antiparkinson Agents